{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:29:09Z","timestamp":1773361749707,"version":"3.50.1"},"reference-count":59,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund","award":["138041"],"award-info":[{"award-number":["138041"]}]},{"name":"Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund","award":["EK\u00d6P-24"],"award-info":[{"award-number":["EK\u00d6P-24"]}]},{"name":"the J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences","award":["138041"],"award-info":[{"award-number":["138041"]}]},{"name":"the J\u00e1nos Bolyai Research Scholarship of the Hungarian Academy of Sciences","award":["EK\u00d6P-24"],"award-info":[{"award-number":["EK\u00d6P-24"]}]},{"name":"Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund","award":["138041"],"award-info":[{"award-number":["138041"]}]},{"name":"Ministry for Culture and Innovation from the source of the National Research, Development and Innovation Fund","award":["EK\u00d6P-24"],"award-info":[{"award-number":["EK\u00d6P-24"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited epidemiological data from Central\u2013Eastern Europe. This study characterized a Hungarian PSC cohort, comparing patients with and without inflammatory bowel disease (IBD), and longitudinally evaluated the predictive efficacy of established prognostic scores (Mayo Risk Score, Amsterdam-Oxford Model [AOM], UK-PSC short\/long). Methods: Data from 135 PSC patients (median diagnosis age 31 years, 57.7% male) were collected yearly at two Hungarian centers, with a median follow-up of 8.8 years. Outcomes included liver transplantation (LT) and liver-related death. Prognostic value of baseline clinical scores was assessed for 2-, 5-, 8-, and 10-year composite outcome. Results: PSC-IBD patients (54.1%) were younger with higher baseline Mayo and AOM scores, and had increased rates of colorectal carcinoma (8.22% vs. 0.00%) and liver transplantation (26.03% vs. 9.68%) within 10 years than PSC-only patients. There were no differences in liver-related mortality or composite outcomes between the groups. All prognostic scores showed good short-term predictive ability for poor outcomes (AUROC at 2 years: 0.858\u20130.958), which diminished over time (AUROC at 10 years: 0.708\u20130.756). The AOM demonstrated the most consistent performance. Persistent alkaline phosphatase (ALP) elevation (\u22652.2\u00d7ULN) 2 years post-diagnosis, despite ursodeoxycholic acid therapy, strongly predicted 10-year adverse outcomes (HR: 3.927, p &lt; 0.001), outperforming formal scoring systems (HR: 2.688\u20131.522). Conclusions: While PSC-IBD patients had more CRC and liver transplantation, overall transplantation-free survival was similar to PSC-only patients. Prognostic utility of current scores declines with longer follow-up; AOM was most stable. Sustained ALP elevation is a robust long-term prognostic indicator.<\/jats:p>","DOI":"10.3390\/diagnostics15172166","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:19:32Z","timestamp":1756282772000},"page":"2166","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Longitudinal Comparison of Currently Used Risk Scores for Prognostication of Primary Sclerosing Cholangitis (PSC) in a Hungarian Bicenter PSC Cohort"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-7757","authenticated-orcid":false,"given":"Peter Laszlo","family":"Ven","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, First Department of Medicine, Medical School, University of P\u00e9cs, 7624 P\u00e9cs, Hungary"},{"name":"K\u00e1lm\u00e1n Laki Doctoral School of Biomedical and Clinical Sciences, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-5498","authenticated-orcid":false,"given":"David","family":"Tornai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"European Reference Network on Hepatological Diseases, ERN RARE-LIVER, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bence","family":"Toth","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"European Reference Network on Hepatological Diseases, ERN RARE-LIVER, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Vitalis","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"European Reference Network on Hepatological Diseases, ERN RARE-LIVER, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-101X","authenticated-orcid":false,"given":"Istvan","family":"Tornai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"European Reference Network on Hepatological Diseases, ERN RARE-LIVER, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamas","family":"Tornai","sequence":"additional","affiliation":[{"name":"Institute of Pancreatic Diseases, Semmelweis University, 1089 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6943-6756","authenticated-orcid":false,"given":"Gabriella","family":"Par","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, First Department of Medicine, Medical School, University of P\u00e9cs, 7624 P\u00e9cs, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-4010","authenticated-orcid":false,"given":"Maria","family":"Papp","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary"},{"name":"European Reference Network on Hepatological Diseases, ERN RARE-LIVER, 4032 Debrecen, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/gut.21.10.870","article-title":"Primary Sclerosing Cholangitis: A Review of Its Clinical Features, Cholangiography, and Hepatic Histology","volume":"21","author":"Chapman","year":"1980","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/BF02361256","article-title":"Primary Sclerosing Cholangitis","volume":"29","author":"Ueno","year":"1994","journal-title":"J. Gastroenterol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1053\/j.gastro.2021.08.032","article-title":"Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis","volume":"161","author":"Barberio","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1111\/liv.15007","article-title":"Global Incidence, Prevalence and Features of Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis","volume":"41","author":"Mehta","year":"2021","journal-title":"Liver Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1055\/s-2006-933565","article-title":"Liver Transplantation in Primary Sclerosing Cholangitis","volume":"26","author":"Foss","year":"2006","journal-title":"Semin. Liver Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.livres.2017.12.002","article-title":"Primary Sclerosing Cholangitis: A Review and Update","volume":"1","author":"Tabibian","year":"2017","journal-title":"Liver Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2013.03.015","article-title":"Update on Primary Sclerosing Cholangitis","volume":"59","author":"Karlsen","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL Clinical Practice Guidelines on Sclerosing Cholangitis","volume":"77","author":"Chazouilleres","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD Practice Guidance on Primary Sclerosing Cholangitis and Cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wunsch, E., Krawczyk, M., Milkiewicz, M., Trottier, J., Barbier, O., Neurath, M.F., Lammert, F., Kremer, A.E., and Milkiewicz, P. (2016). Serum Autotaxin Is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases. Sci. Rep., 6.","DOI":"10.1038\/srep30847"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kruk, B., Liebe, R., Milkiewicz, M., Wunsch, E., Raszeja-Wyszomirska, J., Lammert, F., Milkiewicz, P., and Krawczyk, M. (2018). PNPLA3 p.I148M and TM6SF2 p.E167K Variants Do Not Predispose to Liver Injury in Cholestatic Liver Diseases: A Prospective Analysis of 178 Patients with PSC. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202942"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1007\/s00330-024-10787-4","article-title":"Disease Severity Prognostication in Primary Sclerosing Cholangitis: A Validation of the Anali Scores and Comparison with the Potential Functional Stricture","volume":"34","author":"Messner","year":"2024","journal-title":"Eur. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e70041","DOI":"10.1111\/eci.70041","article-title":"Fatigue and Itch Severity in Patients with PBC and PSC: Prospective Analysis of Two Large Cohorts","volume":"55","author":"Kruk","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jhep.2019.08.013","article-title":"Risk Stratification in Primary Sclerosing Cholangitis: It\u2019s Time to Move on from Replicating Imperfection and Break the Glass Ceiling","volume":"71","author":"Trivedi","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.28128","article-title":"Risk Stratification in Autoimmune Cholestatic Liver Diseases: Opportunities for Clinicians and Trialists","volume":"63","author":"Trivedi","year":"2016","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-Dose Ursodeoxycholic Acid for the Treatment of Primary Sclerosing Cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline Phosphatase at Diagnosis of Primary Sclerosing Cholangitis and 1 Year Later: Evaluation of Prognostic Value","volume":"36","author":"Wang","year":"2016","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.cgh.2012.12.032","article-title":"Association Between Reduced Levels of Alkaline Phosphatase and Survival Times of Patients With Primary Sclerosing Cholangitis","volume":"11","author":"Hultcrantz","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary Sclerosing Cholangitis: Natural History, Prognostic Factors and Survival Analysis","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1016\/0016-5085(91)90673-9","article-title":"Natural History and Prognostic Variables in Primary Sclerosing Cholangitis","volume":"100","author":"Farrant","year":"1991","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/gut.38.4.610","article-title":"Natural History and Prognostic Factors in 305 Swedish Patients with Primary Sclerosing Cholangitis","volume":"38","author":"Olsson","year":"1996","journal-title":"Gut"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0025-6196(11)64614-4","article-title":"A Revised Natural History Model for Primary Sclerosing Cholangitis","volume":"75","author":"Kim","year":"2000","journal-title":"Mayo Clin. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/jhep.2002.31872","article-title":"Time-Dependent Cox Regression Model Is Superior in Prediction of Prognosis in Primary Sclerosing Cholangitis","volume":"35","author":"Boberg","year":"2002","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.51.4.562","article-title":"Natural History of Primary Sclerosing Cholangitis and Prognostic Value of Cholangiography in a Dutch Population","volume":"51","author":"Ponsioen","year":"2002","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1572-0241.2006.00872.x","article-title":"Characterization, Outcome, and Prognosis in 273 Patients with Primary Sclerosing Cholangitis: A Single Center Study","volume":"102","author":"Tischendorf","year":"2007","journal-title":"Am. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A Novel Prognostic Model for Transplant-Free Survival in Primary Sclerosing Cholangitis","volume":"67","author":"Wang","year":"2018","journal-title":"Gut"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/hep.30479","article-title":"Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System","volume":"69","author":"Goode","year":"2019","journal-title":"Hepatology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/hep.30085","article-title":"Primary Sclerosing Cholangitis Risk Estimate Tool (PREsTo) Predicts Outcomes of the Disease: A Derivation and Validation Study Using Machine Learning","volume":"71","author":"Eaton","year":"2020","journal-title":"Hepatology"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Schmeltzer, P.A., and Russo, M.W. (2021). Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194476"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.3748\/wjg.v28.i21.2291","article-title":"Serological Biomarkers for Management of Primary Sclerosing Cholangitis","volume":"28","author":"Tornai","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.dld.2025.02.001","article-title":"PSC-Specific Prognostic Scores Associated with Graft Loss and Overall Mortality in Recurrent PSC after Liver Transplantation","volume":"57","author":"Lytvyak","year":"2025","journal-title":"Dig. Liver Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2015). EASL Clinical Practice Guidelines: Autoimmune Hepatitis. J. Hepatol., 63, 971\u20131004.","DOI":"10.1016\/j.jhep.2015.06.030"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial Diagnosis, Monitoring of Known IBD, Detection of Complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/liv.13548","article-title":"Inflammatory Bowel Disease with Primary Sclerosing Cholangitis: A Danish Population-Based Cohort Study 1977-2011","volume":"38","author":"Nielsen","year":"2018","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/hep.23678","article-title":"Incidence and Prevalence of Primary Sclerosing Cholangitis in a Defined Adult Population in Sweden","volume":"52","author":"Lindkvist","year":"2010","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/00365521.2019.1707277","article-title":"Epidemiology, Risk of Malignancy and Patient Survival in Primary Sclerosing Cholangitis: A Population-Based Study in Finland","volume":"55","author":"Pukkala","year":"2020","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-Based Epidemiology, Malignancy Risk, and Outcome of Primary Sclerosing Cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/00365529850166284","article-title":"Incidence and Prevalence of Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis in a Norwegian Population","volume":"33","author":"Boberg","year":"1998","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"820","DOI":"10.3109\/00365521.2012.682090","article-title":"Fine Mapping and Replication of Genetic Risk Loci in Primary Sclerosing Cholangitis","volume":"47","author":"Srivastava","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.crohns.2011.07.015","article-title":"A Unique Clinical Phenotype of Primary Sclerosing Cholangitis Associated with Crohn\u2019s Disease","volume":"6","author":"Halliday","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Toy, E., Balasubramanian, S., Selmi, C., Li, C.S., and Bowlus, C.L. (2011). The Prevalence, Incidence and Natural History of Primary Sclerosing Cholangitis in an Ethnically Diverse Population. BMC Gastroenterol., 11.","DOI":"10.1186\/1471-230X-11-83"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1053\/j.gastro.2010.10.014","article-title":"Bone Disease in Patients with Primary Sclerosing Cholangitis","volume":"140","author":"Angulo","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0366","DOI":"10.1097\/HC9.0000000000000366","article-title":"African American Race Does Not Confer an Increased Risk of Clinical Events in Patients with Primary Sclerosing Cholangitis","volume":"8","author":"Yazdanfar","year":"2024","journal-title":"Hepatol. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13023-022-02565-6","article-title":"A Common Variant in the Hepatobiliary Phospholipid Transporter ABCB4 Modulates Liver Injury in PBC but Not in PSC: Prospective Analysis in 867 Patients","volume":"17","author":"Kruk","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.3748\/wjg.v21.i6.1956","article-title":"Distinctive Inflammatory Bowel Disease Phenotype in Primary Sclerosing Cholangitis","volume":"21","author":"Janse","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.cgh.2011.08.027","article-title":"Inflammatory Bowel Disease Is Associated with Poor Outcomes of Patients with Primary Sclerosing Cholangitis","volume":"9","author":"Ngu","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis","volume":"152","author":"Strassburg","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.cgh.2021.08.039","article-title":"Epidemiology, Natural History, and Outcomes of Primary Sclerosing Cholangitis: A Systematic Review of Population-Based Studies","volume":"20","author":"Trivedi","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"7746401","DOI":"10.1155\/2021\/7746401","article-title":"Clinical Features and Outcomes of Primary Sclerosing Cholangitis in the Highly Admixed Brazilian Population","volume":"2021","author":"Nardelli","year":"2021","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2036.2012.05063.x","article-title":"The Impact of Ulcerative Colitis on the Long-Term Outcome of Patients with Primary Sclerosing Cholangitis","volume":"35","author":"Navaneethan","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/MEG.0b013e328331c2b7","article-title":"Characteristics and Clinical Course of Primary Sclerosing Cholangitis in France: A Prospective Cohort Study","volume":"22","author":"Garioud","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MEG.0000000000000596","article-title":"Primary Sclerosing Cholangitis Associated with Inflammatory Bowel Disease: An Observational Study in a Southern Europe Population Focusing on New Therapeutic Options","volume":"28","author":"Franceschet","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1053\/j.gastro.2020.05.049","article-title":"Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age","volume":"159","author":"Trivedi","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e00984","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in Primary Sclerosing Cholangitis; a Randomized, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Hatami","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Levy, C., Abouda, G.F., Bilir, B.M., Bonder, A., Bowlus, C.L., Campos-Varela, I., Cazzagon, N., Chandok, N., Cheent, K., and Cortez-Pinto, H. (2025). Safety and Efficacy of Elafibranor in Primary Sclerosing Cholangitis: The ELMWOOD Phase II Randomized-Controlled Trial. J. Hepatol.","DOI":"10.1016\/j.jhep.2025.04.025"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1619","article-title":"Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study","volume":"5","author":"Eksteen","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MOG.0000000000000911","article-title":"Prognostic Modeling in Biliary Diseases","volume":"39","author":"Ciobanu","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, Clinical Utility and Limitations of the Amsterdam-Oxford Model for Primary Sclerosing Cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e00315","DOI":"10.14309\/ctg.0000000000000315","article-title":"Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis","volume":"12","author":"Bossen","year":"2021","journal-title":"Clin. Transl. Gastroenterol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2166\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:24Z","timestamp":1760034804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":59,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["diagnostics15172166"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15172166","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}